Stefan, Norbert

Identification and characterization of metabolically benign obesity in humans

Stefan, N. (2008) · Archives of Internal Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 1,049

Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach

Floegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.-G., Fritsche, A., Häring, H.-U., Hrabě de Angelis, M., Peters, A., et al. (2013) · Diabetes

Metabolomics and Mass Spectrometry StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 988

Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications

Stefan, N., Häring, H.-U., Hu, F. B., & Schulze, M. B. (2013) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 857

High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes

Vozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 717

Obesity and impaired metabolic health in patients with COVID-19

Stefan, N., Birkenfeld, A. L., Schulze, M. B., & Ludwig, D. S. (2020) · Nature Reviews Endocrinology

COVID-19 Clinical Research StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 626

Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans

Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 575

The role of hepatokines in metabolism

Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology

Adipokines, Inflammation, and Metabolic DiseasesLiver Disease Diagnosis and Treatment

Cited by 500

Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study

Eckel, N., Li, Y., Kuxhaus, O., Stefan, N., Hu, F. B., & Schulze, M. B. (2018) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsObesity, Physical Activity, Diet

Cited by 457

Global pandemics interconnected — obesity, impaired metabolic health and COVID-19

Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology

COVID-19 Clinical Research StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 452

Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes

Wagner, R., Heni, M., Tabák, A. G., Machann, J., Schick, F., Randrianarisoa, E., Hrabě de Angelis, M., Birkenfeld, A. L., Stefan, N., Peter, A., et al. (2021) · Nature Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 415

Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis.

Eckel, N., Meidtner, K., Kalle-Uhlmann, T., Stefan, N., & Schulze, M. B. (2016) · European Journal of Preventive Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and Adiposity

Cited by 405

Plasma fetuin-A levels and the risk of type 2 diabetes

Stefan, N., Fritsche, A., Weikert, C., Boeing, H., Joost, H.-G., Häring, H.-U., & Schulze, M. B. (2008) · Diabetes

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 379

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 360

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Schäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t’Hart, L. M., Nijpels, G., et al. (2007) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 308

Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans

Randrianarisoa, E., Lehn-Stefan, A., Wang, X., Hoene, M., Peter, A., Heinzmann, S. S., Zhao, X., Königsrainer, I., Königsrainer, A., Balletshofer, B., et al. (2016) · Scientific Reports

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Disease Prevention

Cited by 296

Fetuin-A Induces Cytokine Expression and Suppresses Adiponectin Production

Hennige, A. M., Staiger, H., Wicke, C., Machicao, F., Fritsche, A., Häring, H.-U., & Stefan, N. (2008) · PLoS ONE

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 282

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 273

Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment

Stefan, N., & Schulze, M. B. (2023) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 215

Intermuscular adipose tissue (IMAT): Association with other adipose tissue compartments and insulin sensitivity

Boettcher, M., Machann, J., Stefan, N., Thamer, C., Häring, H., Claussen, C. D., Fritsche, A., & Schick, F. (2009) · Journal of Magnetic Resonance Imaging

Cardiovascular Disease and AdiposityAdipokines, Inflammation, and Metabolic Diseases

Cited by 214

Phenotypes of prediabetes and stratification of cardiometabolic risk

Stefan, N., Fritsche, A., Schick, F., & Häring, H.-U. (2016) · The Lancet Diabetes & Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 208

Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator–Activated Receptor (PPAR)-δ and Is of Metabolic Relevance in Humans

Staiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., Machicao, F., Stefan, N., Fritsche, A., & Häring, H.-U. (2009) · Diabetes

Peroxisome Proliferator-Activated ReceptorsLipid metabolism and disorders

Cited by 183

Central Insulin Administration Improves Whole-Body Insulin Sensitivity via Hypothalamus and Parasympathetic Outputs in Men

Heni, M., Wagner, R., Kullmann, S., Veit, R., Mat Husin, H., Linder, K., Benkendorff, C., Peter, A., Stefan, N., Häring, H.-U., et al. (2014) · Diabetes

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 167

Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat‐selective MRI and volume‐localized 1H‐MR spectroscopy

Machann, J., Thamer, C., Schnoedt, B., Stefan, N., Haring, H., Claussen, C. D., Fritsche, A., & Schick, F. (2006) · Magnetic Resonance in Medicine

Advanced MRI Techniques and ApplicationsLiver Disease Diagnosis and Treatment

Cited by 162

Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans

Stefan, N., & Häring, H.-U. (2013) · Nature Medicine

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 160